Latest Developments
New approvals, Turkey licence and SGK reimbursement news by cancer type, notable studies.
Do you have a question?You can write via WhatsApp for an appointment or a second opinion.
WhatsApp AppointmentLatest Developments
Sarcomas: Latest Developments
Sources reviewed by: Assoc. Prof. Dr. Ali OğulLast updated:
Short summaries of recently published approvals, licensing and reimbursement regulations in Turkey, and notable studies in sarcomas. For general information about the disease, see the Sarcomas page.
News type
Showing 1 development
In relapsed osteosarcoma, the antibody–drug conjugate risvutatug rezetecan prolonged disease control compared with chemotherapy (ARTEMIS-011)
Osteosarcoma is a bone cancer seen mostly in adolescents and young adults; when it recurs after several lines of treatment, options have been very limited for many years. In the phase 3 ARTEMIS-011 trial conducted in China, 122 patients aged 12 years and older whose disease had progressed after at least two previous treatments were randomly assigned to risvutatug rezetecan, which binds to the B7-H3 protein on the tumour surface and carries the drug directly into the tumour cell, or to gemcitabine plus docetaxel chemotherapy. Median time until the disease progressed was 5.5 versus 1.4 months (HR 0.33). Overall survival data are not yet mature. Serious side effects, especially low blood counts, were more frequent in the drug group; no treatment-related deaths were reported. The study is small, follow-up is short and the drug is not yet approved anywhere. In osteosarcoma, treatment is planned through joint assessment by orthopaedic oncology, medical oncology, paediatric oncology where needed, radiology and pathology.
These results are clinical trial data presented at a congress; they do not imply an approved use. Treatment decisions are made at a multidisciplinary tumour board, considering tumour type, stage, general health and previous treatments together.
Status in Turkey: No product containing risvutatug rezetecan is on the TİTCK licensed medicinal products list dated 16.10.2026. There is no licence or SGK reimbursement in Turkey; treatment options should be discussed with your doctor.
There are no developments to show for this selection. You can change the filters and try again.
How is this page prepared?
- FDA approvals are taken from the oncology approval notifications of the US Food and Drug Administration. An FDA approval does not mean that the drug can be used in Turkey.
- Turkey licences are verified against the TİTCK list of licensed products and the approved Summary of Product Characteristics (KÜB) documents. The licence date is not necessarily the date on which the drug is available in a pharmacy or hospital.
- SGK reimbursement news is based on SUT amendments published in the Official Gazette and on the SGK list of reimbursed medicines (EK-4/A). Reimbursement is limited to the conditions written in the SUT.
- Promising studies are results published in peer-reviewed journals; they are not yet an approved treatment and do not amount to a drug approval.
Drugs are referred to by their active ingredient names. Numerical results are reported as stated in the source; if the hazard ratio (HR) is below 1, the result favours the new treatment.
The news on this page is for general information only; it is not a diagnosis or treatment recommendation. Whether a treatment is suitable for you is decided together with your physician after assessing the characteristics of your disease.
Appointment
Is a new treatment right for you?
Assessing what a development means for your situation requires considering your diagnosis, stage, molecular test results and previous treatments together. You can write or call to make an appointment or request a second opinion.
The news on this page is for general information only; it is not a diagnosis or treatment recommendation. Whether a treatment is suitable for you is decided together with your physician after assessing the characteristics of your disease.